Pilot study for functional and structural MR Imaging of Endobroncial valve recipients using hyperpoloarized XENON-129
We propose to use gas Magnetic Resonance Imaging (MRI) using the inhaled contrast agent, hyperpolarized (HP) xenon-129, to study the lungs of 20 volunteers who have received or will receive endobronchial valve (EBV) therapy as a treatment for COPD. Since its recent FDA approval, investigators have yet to explicitly assess the overall affect of this therapy on overall lung functionality. This protocol will assess any potential changes in proper lung structure and functionality by using HP xenon-129 MRI. Once inhaled, this gas can provide information regarding lung structure and functionality, while also providing information regarding the changes that occur in the lung from EBV therapy and the efficacy of the therapy for treating COPD.
Quality of Life Pulmonary Questionnaires:
o St. Georges Respiratory Questionnaire
o Modified Medical Research Council Questionnaire o COPD Assessment Test (CAT)
Brief physical exam
Pulmonary function test (if not completed with your physician prior toattending the study)
Practice for the breathing procedure being performed during the study
MRI scanning using the inhaled MRI contrast agent Hyperpolarized Xenon-129 (HP 129Xe)Your participation will last for up to two years. Over the course of your participation, you will be contacted to attend up to five follow up visits after your initial baseline visit.
- Study Identifier: 834424
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required